IPM Take
This is the uncomfortable kind of result for global oncology. It was generated in China, it challenges an established immunotherapy backbone, and it asks whether Western systems will take China-origin evidence seriously before global confirmatory data arrive. The science is promising. The access politics are complicated.
Executive Summary
The phase III HARMONi-6 trial showed a statistically significant overall survival benefit for ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC in China. The trial’s primary endpoint was progression-free survival, while overall survival was a key secondary endpoint.
Twenty-four-month overall survival was 64.7% with ivonescimab plus chemotherapy versus 48.6% with tislelizumab plus chemotherapy. The results were presented at ASCO 2026 and simultaneously published in The Lancet.
Why it matters
- Regulators: Need to decide how single-region China data should inform future global filings and evidence expectations.
- Clinicians: May see pressure to compare PD-1/VEGF bispecific strategies against current PD-1 or PD-L1 chemo backbones.
- Industry / innovation partners: China-origin oncology assets are no longer peripheral; they are shaping global competitive strategy.
The old assumption was simple: the global lung cancer standard would mostly be defined by multinational trials led from the US, Europe and Japan. HARMONi-6 makes that assumption look dated.
Ivonescimab is a PD-1/VEGF bispecific antibody. In HARMONi-6, it did not compete against chemotherapy alone. It went head-to-head against a PD-1 inhibitor plus chemotherapy, one of the core modern treatment logics in advanced NSCLC. That is why the survival result matters.
The caveat is also important. HARMONi-6 was conducted in China, and global practice will need broader confirmation, especially across different populations, comparators and regulatory systems. But dismissing the result because it is China-origin would be lazy. China’s oncology development engine is now producing data that global systems have to interpret seriously.
The affected population is patients with previously untreated advanced squamous NSCLC, irrespective of PD-L1 expression. Squamous disease has historically been harder to treat and less biomarker-rich than non-squamous NSCLC, which makes a survival-improving regimen especially relevant.
For IPM, HARMONi-6 is a signal about the new geography of innovation. The question is no longer whether China will produce oncology drugs. It is whether global health systems can evaluate, validate and integrate China-origin evidence without political reflexes getting ahead of clinical judgement.
